Skip to main content

Table 3 Multivariate analysis of factors affecting RFS of patients with breast cancers of different molecular subtypes

From: KIBRA; a novel biomarker predicting recurrence free survival of breast cancer patients receiving adjuvant therapy

Clinico-pathological feature

Luminal A

Luminal B

TNBC with basal-like p value, (HR;CI)


p value (HR;CI)

p value (HR;CI)

p value (HR; CI)

Age (≤ 35, 36–60,> 60 years)


Lymph node stage


 Stage 2


0.031 (3.805; 1.130–12.811)

 Stage 3


0.005 (6.487;1.740–24.180)



5.506 (1.710–17.734)

Overall KIBRA-low

  1. *Significant only for the lymph node stage 3;p, significance; HR, hazard ratio; CI, confidence interval; HER2, human epidermal growth factor receptor2; KIBRA-low; low expression of KIBRA in both cytoplasm and nucleus